mutLBSgeneDB

mutLBSgeneDB
mutated Ligand Binding Site gene DataBase

Home

Download

 Statistics

Help

About Us
Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for KDR
Gene summary
Basic gene Info.Gene symbolKDR
Gene namekinase insert domain receptor
SynonymsCD309|FLK1|VEGFR|VEGFR2
CytomapUCSC genome browser: 4q11-q12
Type of geneprotein-coding
RefGenesNM_002253.2,
Descriptionfetal liver kinase 1fetal liver kinase-1kinase insert domain receptor (a type III receptor tyrosine kinase)protein-tyrosine kinase receptor Flk-1soluble VEGFR2tyrosine kinase growth factor receptorvascular endothelial growth factor receptor 2
Modification date20141221
dbXrefs MIM : 191306
HGNC : HGNC
Ensembl : ENSG00000128052
HPRD : 01867
Vega : OTTHUMG00000128734
ProteinUniProt: P35968
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_KDR
BioGPS: 3791
PathwayNCI Pathway Interaction Database: KDR
KEGG: KDR
REACTOME: KDR
Pathway Commons: KDR
ContextiHOP: KDR
ligand binding site mutation search in PubMed: KDR
UCL Cancer Institute: KDR
Assigned class in mutLBSgeneDBB: This gene belongs to targetable_mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO IDGO TermPubMed ID
GO:0001934positive regulation of protein phosphorylation19033661
GO:0008284positive regulation of cell proliferation7929439
GO:0008360regulation of cell shape7929439
GO:0014068positive regulation of phosphatidylinositol 3-kinase signaling9804796
GO:0018108peptidyl-tyrosine phosphorylation10037737
GO:0030335positive regulation of cell migration7929439
GO:0035924cellular response to vascular endothelial growth factor stimulus10102632
GO:0038084vascular endothelial growth factor signaling pathway10022831
GO:0043410positive regulation of MAPK cascade11387210
GO:0046777protein autophosphorylation10037737
GO:0048010vascular endothelial growth factor receptor signaling pathway10102632
GO:0050927positive regulation of positive chemotaxis7929439
GO:0051770positive regulation of nitric-oxide synthase biosynthetic process10600473
GO:0051894positive regulation of focal adhesion assembly12820653
GO:2000352negative regulation of endothelial cell apoptotic process9804796


Top
Ligand binding site mutations for KDR

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
L1019S1021LBLCA1
C1024R1022QCOAD1
I1044V1042GCOAD1
D1052R1051QKIRC1
A866T864KLUAD1
R842R842LLUAD1
L1019S1021LLUAD1
V898N897ILUAD1
V914M913ILUAD1
C1024R1022PLUSC1
D1052D1052NSKCM1
L1035S1037LSKCM1
I1044V1042ASTAD1
D1052I1053MUCEC1
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.


Top
Protein structure related information for KDR
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
I1044V1042G-1.7232834
D1052I1053M-1.7021051
I1044V1042A-1.4579404
D1052R1051Q-1.446014
C1024R1022Q-1.3302496
C1024R1022P-1.1333039
A866T864K-1.0521383
V914M913I-0.85453926
V898N897I-0.55509896
D1052D1052N-0.44708374
R842R842L-0.41527311
L1019S1021L-0.35221967
L1035S1037L-0.24238725
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for KDR from PDB

Top
Differential gene expression and gene-gene network for KDR
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of KDR and the right PPI network was created from samples without mutations in the LBS of KDR. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Top

Top
Phenotype information for KDR
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type
umls:C1458155Breast Neoplasms11AlteredExpression, Biomarker, GeneticVariation
umls:C0027686Neovascularization, Pathologic4Biomarker, GeneticVariation
umls:C0001418Adenocarcinoma3AlteredExpression, Biomarker
umls:C0018923Hemangiosarcoma3Biomarker, GeneticVariation
umls:C0035126Reperfusion Injury2Biomarker
umls:C0009404Colorectal Neoplasms2AlteredExpression, Therapeutic
umls:C0011881Diabetic Nephropathies2Biomarker
umls:C0030297Pancreatic Neoplasms2Biomarker, Therapeutic
umls:C1865871Hemangioma, capillary infantile1Biomarker, GeneticVariation
umls:C2937358Cerebral Hemorrhage1Biomarker
umls:C0014556Epilepsy, Temporal Lobe1Biomarker
umls:C0014859Esophageal Neoplasms1Biomarker
umls:C0023904Liver Neoplasms, Experimental1Biomarker
umls:C0151744Myocardial Ischemia1Biomarker
umls:C0029422Osteochondrodysplasias1Biomarker
umls:C0036341Schizophrenia1Biomarker
umls:C0041948Uremia1Biomarker

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Top
Pharmacological information for KDR
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure
Approved|investigationalDB00398SorafenibSmall molecule
Approved|investigationalDB01268SunitinibSmall molecule
ExperimentalDB04727N-(4-{4-AMINO-6-[4-(METHYLOXY)PHENYL]FURO[2,3-D]PYRIMIDIN-5-YL}PHENYL)-N'-[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]UREASmall molecule
InvestigationalDB04849AZD2171Small molecule
InvestigationalDB04879VatalanibSmall molecule
InvestigationalDB05014XL999Small molecule
InvestigationalDB05030XL880Small molecule
InvestigationalDB05075TG100801Small molecule
InvestigationalDB05146XL820Small molecule
InvestigationalDB05153XL184Small molecule
InvestigationalDB05198CYC116Small molecule
Approved|investigationalDB05578RamucirumabBiotech
InvestigationalDB06080ABT-869Small molecule
InvestigationalDB06101IMC-1C11Biotech
ApprovedDB06589PazopanibSmall molecule
Approved|investigationalDB06626AxitinibSmall molecule
ExperimentalDB069384-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamideSmall molecule
ExperimentalDB07183N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamideSmall molecule
ExperimentalDB07274N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamideSmall molecule
ExperimentalDB073266-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamideSmall molecule
ExperimentalDB07333N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDESmall molecule
ExperimentalDB07334N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINESmall molecule
ExperimentalDB075143-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-oneSmall molecule
ExperimentalDB075283-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-oneSmall molecule
ExperimentalDB07537N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamideSmall molecule
ExperimentalDB08042N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamineSmall molecule
ExperimentalDB08519N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamineSmall molecule
ApprovedDB08875CabozantinibSmall molecule
ApprovedDB08896RegorafenibSmall molecule
ApprovedDB08901PonatinibSmall molecule
ApprovedDB09078LenvatinibSmall molecule
ApprovedDB09079NintedanibSmall molecule

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of KDR go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS
608N-(4-PHENOXYPHENYL)-2-[(PYRIDIN-4-YLMETHYL)AMINO]NICOTINAMIDE2p2iBA866 C1024 L1035
2RLN-(4-CHLOROPHENYL)-7-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]-2,3-DIHYDRO-1,4-BENZOXAZINE-4-CARBOXAMIDE2rl5AA866 L1019 L1035
C92N'-(6-AMINOPYRIDIN-3-YL)-N-(2-CYCLOPENTYLETHYL)-4-METHYL-BENZENE-1,3-DICARBOXAMIDE3cpbBA866 L1019 L1035
8574-({2-[(4-CHLORO-3-{[(2S)-1-METHYLPYRROLIDIN-2-YL]METHOXY}PHENYL)AMINO]-1,3-BENZOXAZOL-5-YL}OXY)-N-METHYLPYRIDINE-2-CARBOXAMIDE2qu6AA866 L1019 L1035 I1044
8574-({2-[(4-CHLORO-3-{[(2S)-1-METHYLPYRROLIDIN-2-YL]METHOXY}PHENYL)AMINO]-1,3-BENZOXAZOL-5-YL}OXY)-N-METHYLPYRIDINE-2-CARBOXAMIDE2qu6BA866 L1019 L1035 I1044
BAX4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE4asdAA866 L1019 L1035 I1044
9944-(2-ANILINOPYRIDIN-3-YL)-N-(3,4,5-TRIMETHOXYPHENYL)-1,3,5-TRIAZIN-2-AMINE2p2hAA866 L1035
XINMETHYL (3Z)-3-{[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO}PHENYL)AMINO](PHENYL)METHYLIDENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE3c7qAA866 L1035
4TT4,5,6,11-TETRAHYDRO-1H-PYRAZOLO[4',3':6,7]CYCLOHEPTA[1, 2-B]INDOLE3vidAA866 L1035
B49SUNITINIB4agdAA866 L1035
AV9TIVOZANIB1-{2-CHLORO-4-[(6,7-DIMETHOXYQUINOLIN-4-YL) OXY]PHENYL}-3-[(3E)-5-METHYLISOXAZOL-3(2H)- YLIDENE]UREA4aseAA866 L1035
LEVLENVATINIB4-{3-CHLORO-4-[(CYCLOPROPYLCARBAMOYL)AMINO]PHENOXY}-7- METHOXYQUINOLINE-6-CARBOXAMIDE3wzdAA866 L1035
RAJN-{3-[3-(DIMETHYLAMINO)PROPYL]-5-(TRIFLUOROMETHYL)PHENYL}-4-METHYL-3-[(3-PYRIMIDIN-4-YLPYRIDIN-2-YL)AMINO]BENZAMIDE3be2AA866 L1035 I1044
K11N-[4-({3-[2-(METHYLAMINO)PYRIMIDIN-4-YL]PYRIDIN-2-YL}OXY)NAPHTHALEN-1-YL]-6-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOL-2-AMINE3ewhAA866 V898 L1019 L1035
03XN-{4-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]-3-FLUOROPHENYL}-1,5-DIMETHYL-3-OXO-2-PHENYL-2,3-DIHYDRO-1H-PYRAZOLE-4-CARBOXAMIDE3u6jAA866 V898 L1019 L1035
2764-[[2-[[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO]-3H-BENZIMIDAZOL-5-YL]OXY]-N-METHYL-PYRIDINE-2-CARBOXAMIDE2qu5AA866 V898 L1019 L1035 I1044
42Q1-{2-FLUORO-4-[(5-METHYL-5H-PYRROLO[3,2-D]PYRIMIDIN-4-YL)OXY]PHENYL}-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA3vheAA866 V898 L1019 L1035 I1044
C193-(2-AMINOQUINAZOLIN-6-YL)-1-(3,3-DIMETHYLINDOLIN-6-YL)-4-METHYLPYRIDIN-2(1H)-ONE3cp9AA866 V898 L1035
C193-(2-AMINOQUINAZOLIN-6-YL)-1-(3,3-DIMETHYLINDOLIN-6-YL)-4-METHYLPYRIDIN-2(1H)-ONE3cp9BA866 V898 L1035
C523-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-1-[3-(TRIFLUOROMETHYL)PHENYL]PYRIDIN-2(1H)-ONE3cpcAA866 V898 L1035 I1044
C523-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-1-[3-(TRIFLUOROMETHYL)PHENYL]PYRIDIN-2(1H)-ONE3cpcBA866 V898 L1035 I1044
A966-CHLORO-N-PYRIMIDIN-5-YL-3-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}-1,2-BENZISOXAZOLE-7-CARBOXAMIDE3dtwBA866 V898 L1035 I1044
0KFN-[3-({2-[(CYCLOPROPYLCARBONYL)AMINO]IMIDAZO[1,2- B]PYRIDAZIN-6-YL}OXY)PHENYL]-1,3-DIMETHYL-1H-PYRAZOLE- 5-CARBOXAMIDE3vo3AA866 V898 L1035 I1044
BAX4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE3wzeAA866 V898 L1035 I1044
C92N'-(6-AMINOPYRIDIN-3-YL)-N-(2-CYCLOPENTYLETHYL)-4-METHYL-BENZENE-1,3-DICARBOXAMIDE3cpbAA866 V898 V914 L1019 L1035
A966-CHLORO-N-PYRIMIDIN-5-YL-3-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}-1,2-BENZISOXAZOLE-7-CARBOXAMIDE3dtwAA866 V898 V914 L1019 L1035 I1044
0JA2-CHLORO-3-(1-CYANOCYCLOPROPYL)-N-[5-({2-[(CYCLOPROPYLCARBONYL)AMINO][1,3]THIAZOLO[5,4-B]PYRIDIN-5-YL}OXY)-2-FLUOROPHENYL]BENZAMIDE3vntAA866 V898 V914 L1019 L1035 I1044
5T22-(PYRIDIN-4-YLMETHYLAMINO)-~{N}-[3-(TRIFLUOROMETHYL) PHENYL]BENZAMIDE5ew3AA866 V898 V914 L1019 L1035 I1044
5T22-(PYRIDIN-4-YLMETHYLAMINO)-~{N}-[3-(TRIFLUOROMETHYL) PHENYL]BENZAMIDE5ew3BA866 V898 V914 L1019 L1035 I1044
608N-(4-PHENOXYPHENYL)-2-[(PYRIDIN-4-YLMETHYL)AMINO]NICOTINAMIDE2p2iAA866 V914 L1019 C1024 L1035
706MOTESANIB3eflBA866 V914 L1019 L1035
00JN,2-DIMETHYL-6-{[7-(2-MORPHOLIN-4-YLETHOXY)QUINOLIN-4-YL]OXY}-1-BENZOFURAN-3-CARBOXAMIDE2xirAA866 V914 L1035
900N-(4-CHLOROPHENYL)-6-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]NAPHTHALENE-1-CARBOXAMIDE3b8qAA866 V914 L1035
900N-(4-CHLOROPHENYL)-6-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]NAPHTHALENE-1-CARBOXAMIDE3b8qBA866 V914 L1035
887N-CYCLOPROPYL-6-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]NAPHTHALENE-1-CARBOXAMIDE3b8rAA866 V914 L1035
887N-CYCLOPROPYL-6-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]NAPHTHALENE-1-CARBOXAMIDE3b8rBA866 V914 L1035
706MOTESANIB3eflAA866 V914 L1035
AXIAXITINIBN-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6-YLSULFANYL)-BENZAMIDE4ag8AA866 V914 L1035
AXIAXITINIBN-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6-YLSULFANYL)-BENZAMIDE4agcAA866 V914 L1035
BPK{3-[(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL) METHOXY]PHENYL}METHANOL3vhkAV898 V914 L1019
AAZN-(5-ETHYLSULFONYL-2-METHOXYPHENYL)-5-(3-PYRIDIN-2-YLPHENYL)-1,3-OXAZOL-2-AMINE1y6aAV914
AAXN-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE1y6bAV914
GIGMETHYL (5-{4-[({[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-1H-BENZIMIDAZOL-2-YL)CARBAMATE2oh4AV914
KIMN~4~-METHYL-N~4~-(3-METHYL-1H-INDAZOL-6-YL)-N~2~-(3,4,5-TRIMETHOXYPHENYL)PYRIMIDINE-2,4-DIAMINE3cjgAV914


Top
Conservation information for LBS of KDR
Multiple alignments for P35968 in multiple species
LBSAA sequence# speciesSpecies
A866TCRTVAVKMLK1Homo sapiens
A866TCTTVAVKMLK1Danio rerio
A866TCKTVAVKMLK1Rattus norvegicus
C1024LASRKCIHRDL3Homo sapiens, Danio rerio, Rattus norvegicus
C1045NVVKICDFGLA2Homo sapiens, Rattus norvegicus
C1045SVVKICDFGLA1Danio rerio
C919VIVEFCKFGNL2Homo sapiens, Rattus norvegicus
C919VIVEYCKHGNL1Danio rerio
D1046VVKICDFGLAR3Homo sapiens, Danio rerio, Rattus norvegicus
D1052FGLARDIYKDP2Homo sapiens, Rattus norvegicus
D1052FGLARDVYKDP1Danio rerio
E251CTARTELNVGI1Homo sapiens
E251CTAHTELNVGI1Danio rerio
E251CTARTELNVGL1Rattus norvegicus
E850FGQVIEADAFG2Homo sapiens, Rattus norvegicus
E850FGQVVEATAYG1Danio rerio
E885RALMSELKILI3Homo sapiens, Danio rerio, Rattus norvegicus
E917LMVIVEFCKFG2Homo sapiens, Rattus norvegicus
E917LMVIVEYCKHG1Danio rerio
F1047VKICDFGLARD3Homo sapiens, Danio rerio, Rattus norvegicus
F918MVIVEFCKFGN2Homo sapiens, Rattus norvegicus
F918MVIVEYCKHGN1Danio rerio
F921VEFCKFGNLST2Homo sapiens, Rattus norvegicus
F921VEYCKHGNLSS1Danio rerio
G220IVVVVGYRIYD1Homo sapiens
G220IVAVVGYKIYD1Danio rerio
G220IVLVVGYRIYD1Rattus norvegicus
G841LGKPLGRGAFG2Homo sapiens, Rattus norvegicus
G841LGEPLGRGAFG1Danio rerio
G843KPLGRGAFGQV2Homo sapiens, Rattus norvegicus
G843EPLGRGAFGQV1Danio rerio
G922EFCKFGNLSTY2Homo sapiens, Rattus norvegicus
G922EYCKHGNLSSY1Danio rerio
H1026SRKCIHRDLAA3Homo sapiens, Danio rerio, Rattus norvegicus
I1025ASRKCIHRDLA3Homo sapiens, Danio rerio, Rattus norvegicus
I1044KNVVKICDFGL2Homo sapiens, Rattus norvegicus
I1044NSVVKICDFGL1Danio rerio
I888MSELKILIHIG3Homo sapiens, Danio rerio, Rattus norvegicus
I892KILIHIGHHLN3Homo sapiens, Danio rerio, Rattus norvegicus
K868RTVAVKMLKEG1Homo sapiens
K868TTVAVKMLKEG1Danio rerio
K868KTVAVKMLKEG1Rattus norvegicus
K920IVEFCKFGNLS2Homo sapiens, Rattus norvegicus
K920IVEYCKHGNLS1Danio rerio
L1019KGMEFLASRKC3Homo sapiens, Danio rerio, Rattus norvegicus
L1035AARNILLSEKN2Homo sapiens, Rattus norvegicus
L1035AARNILLSENS1Danio rerio
L840KLGKPLGRGAF2Homo sapiens, Rattus norvegicus
L840KLGEPLGRGAF1Danio rerio
L889SELKILIHIGH3Homo sapiens, Danio rerio, Rattus norvegicus
N923FCKFGNLSTYL2Homo sapiens, Rattus norvegicus
N923YCKHGNLSSYL1Danio rerio
R1027RKCIHRDLAAR3Homo sapiens, Danio rerio, Rattus norvegicus
R222VVVGYRIYDVV1Homo sapiens
R222AVVGYKIYDLT1Danio rerio
R222LVVGYRIYDVV1Rattus norvegicus
R842GKPLGRGAFGQ2Homo sapiens, Rattus norvegicus
R842GEPLGRGAFGQ1Danio rerio
V848GAFGQVIEADA2Homo sapiens, Rattus norvegicus
V848GAFGQVVEATA1Danio rerio
V867CRTVAVKMLKE1Homo sapiens
V867CTTVAVKMLKE1Danio rerio
V867CKTVAVKMLKE1Rattus norvegicus
V898GHHLNVVNLLG3Homo sapiens, Danio rerio, Rattus norvegicus
V899HHLNVVNLLGA3Homo sapiens, Danio rerio, Rattus norvegicus
V914GGPLMVIVEFC2Homo sapiens, Rattus norvegicus
V914GGPLMVIVEYC1Danio rerio
V916PLMVIVEFCKF2Homo sapiens, Rattus norvegicus
V916PLMVIVEYCKH1Danio rerio
Y221VVVVGYRIYDV1Homo sapiens
Y221VAVVGYKIYDL1Danio rerio
Y221VLVVGYRIYDV1Rattus norvegicus


Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas